ENANTA PHARMACEUTICALS INC
ENTA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ENTA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ENTA
Enanta Pharmaceuticals Inc. (ENTA) is a biotechnology company focused on developing small molecule drugs for viral infections and immunology, with a marketed hepatitis C virus (HCV) treatment and a pipeline in respiratory syncytial virus (RSV) and immunology.
Key risk: Clinical development risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$396.1M
Cash Runway
55.9 moLead Asset
EDP-938 (Phase 2)
Next Catalyst
Phase3_Topline · Aug 31, 2026Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 311 clinical trials · 27 catalysts for ENANTA PHARMACEUTICALS INC.
Similar companies
Enanta Pharmaceuticals Inc. (ENTA) is a biotechnology company focused on developing small molecule drugs for viral infections and immunology, with a marketed hepatitis C virus (HCV) treatment and a pipeline in respiratory syncytial virus (RSV) and immunology.
- Enanta has a marketed HCV treatment, MAVYRET/MAVIRET, approved for chronic and acute HCV in the U.S. and EU [sec_mda · as of 2026-08-12].
- The company is advancing zelicapavir (RSV) in a pediatric Phase 2/3 trial and EDP-978 (immunology) in Phase 1 [sec_mda · as of 2026-08-12].
- As of June 30, 2026, Enanta reported cash and equivalents of $33.4M, total revenue of $14.4M, and a net loss of -$19.5M [sec].
- Enanta expects its cash runway to fund operations into fiscal 2029, but this is a forward-looking projection subject to risks [sec_mda · as of 2026-08-12].
- The company has funded operations primarily through royalty payments from AbbVie and a $200.0M royalty sale payment received in April 2023 [sec_mda · as of 2026-08-12].
What works
- Enanta has a commercially approved HCV product (MAVYRET/MAVIRET) generating royalty revenue, providing a financial base [sec_mda · as of 2026-08-12].
- The company has a diversified pipeline targeting RSV (zelicapavir) and immunology (EDP-978), with clinical trials underway [sec_mda · as of 2026-08-12].
- Enanta projects its cash runway into fiscal 2029, suggesting sufficient liquidity for near-term operations [sec_mda · as of 2026-08-12].
What to weigh
- Enanta reported a net loss of -$19.5M for the quarter ended June 30, 2026, indicating ongoing unprofitability [sec].
- The company's pipeline is in early-to-mid stages, with no approved products beyond HCV, and development is subject to high uncertainty [sec_mda · as of 2026-08-12].
- Enanta is dependent on collaborations (e.g., AbbVie) and external financing; future capital requirements are difficult to forecast [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Enanta has a marketed HCV treatment approved for acute HCV.
“MAVYRET and MAVIRET were also approved as the first and only treatments for acute HCV infection in the United States and the European Union in June 2025 and June 2026, respectively.”
SEC MD&A · August 12, 2026
Enanta is conducting a Phase 2/3 trial of zelicapavir in pediatric RSV patients.
“clinical trial of zelicapavir in pediatric patients with RSV, and a Phase 1 clinical trial of EDP-978, our lead immunology program.”
SEC MD&A · August 12, 2026
Enanta expects cash runway into fiscal 2029.
“and capital expenditure requirements into fiscal 2029.”
SEC MD&A · August 12, 2026
Enanta funded operations via a $200M royalty sale payment in April 2023.
“a $200.0 million payment received in April 2023 from our royalty sale agreement”
SEC MD&A · August 12, 2026
Catalyst timeline
- 2026-08-31 · Phase3_Topline — Phase 3 Topline: Comparison of Efficacy of Tranexamic Acid Versus Vasopressin in Blood Loss Among Placenta Previa Pat — Topline results from a Phase 3 trial comparing tranexamic acid vs. vasopressin for blood loss in placenta previa patients.
- 2026-12-30 · Phase3_Topline — Phase 3 Topline: A Randomized, Open, Multicenter Phase III Clinical Trial of Combination of Sintilimab Injection (IBI — Topline data from a Phase 3 trial of sintilimab combination therapy.
- 2026-12-31 · Phase3_Topline · pertuzumab — Phase 3 Topline: A Single-Arm Open-Label Multi-Centre Extension Study of Pertuzumab Administered As a Single Agent or — Topline results from a Phase 3 extension study of pertuzumab as monotherapy or combination.
- 2027-01-01 · Phase3_Topline — Phase 3 Topline: A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Ad — Topline data from a Phase 3 trial of maintenance nivolumab vs. observation in locally advanced cancer.
- 2027-04-01 · Phase3_Topline — Phase 3 Topline: Effect of a Healthy Food Voucher on Blood Glucose Control in People With Type 2 Diabetes or Prediabe — Topline results from a Phase 3 trial of a healthy food voucher on blood glucose control.
- 2027-08-30 · Phase3_Topline — Phase 3 Topline: A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 P — Topline data from a Phase 3 diagnostic performance study of [¹⁸F]FAPI-74 PET imaging.
- 2027-10-02 · Phase3_Topline — Phase 3 Topline: TENACITY - A Phase III, Prospective, Randomized, Open-label, Blinded Endpoint Assessment (PROBE) to — Topline results from the TENACITY Phase 3 trial with blinded endpoint assessment.
- 2027-11-16 · Phase3_Topline — Phase 3 Topline: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficac — Topline data from a Phase 3 trial comparing efficacy of an active comparator in a masked study.
Risks & what to watch (4)›
Key risks
- Clinical development risk — Pipeline candidates (RSV, immunology) are in early-to-mid stages; success is uncertain and requires significant additional trials [sec_mda · as of 2026-08-12].
- Financial sustainability — Net loss of -$19.5M in Q3 2026; reliance on royalty revenue and external funding for operations [sec].
- Dependence on collaborations — Operations funded by AbbVie royalties and a royalty sale; future collaborations are uncertain [sec_mda · as of 2026-08-12].
- Competition and technology — Biotech industry risks include competition from technological innovations and regulatory hurdles [sec_mda · as of 2026-08-12].
What to watch
- Phase 2/3 topline data for zelicapavir in pediatric RSV, expected by end of 2026 [sec_mda · as of 2026-08-12].
- Phase 1 data for EDP-978 (immunology) and any updates on preclinical immunology programs [sec_mda · as of 2026-08-12].
- Changes in royalty revenue from AbbVie and any new collaboration or licensing deals [sec_mda · as of 2026-08-12].
- Cash burn rate and any updates to the projected cash runway into fiscal 2029 [sec_mda · as of 2026-08-12].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run ENANTA PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ENANTA PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
55.9 months
D/E 1.94 · 0% dilution
Lead: Approved
4 candidates
27 upcoming, next in ~1d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
130
Total value held
$343.3M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 7,568,110 | $95.4M |
| blackrock, inc. | 3,103,768 | $39.2M |
| farallon capital management llc | 2,871,862 | $36.3M |
| vanguard capital management llc | 2,356,098 | $29.8M |
| deep track capital, lp | 1,956,867 | $24.7M |
| vanguard portfolio management llc | 948,904 | $12.0M |
| millennium management llc | 882,097 | $11.1M |
| geode capital management, llc | 725,061 | $9.2M |
| renaissance technologies llc | 665,258 | $8.4M |
| state street corp | 562,106 | $7.1M |
Showing top 10 of 130 institutional holders of ENANTA PHARMACEUTICALS INC. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 8.9%
- Days to cover
- 18.2
- Shares short
- 2,155,192
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ENTA short interestGovernance
Frequently asked questions
What is the AI investment thesis for ENANTA PHARMACEUTICALS INC?
Enanta Pharmaceuticals Inc. (ENTA) is a biotechnology company focused on developing small molecule drugs for viral infections and immunology, with a marketed hepatitis C virus (HCV) treatment and a pipeline in respiratory syncytial virus (RSV) and immunology.
What is ENANTA PHARMACEUTICALS INC's lead drug candidate?
ENANTA PHARMACEUTICALS INC's most advanced tracked candidate is EDP-938 (Phase 2) for Respiratory Syncytial Virus (RSV); RSV Infection.
What is ENANTA PHARMACEUTICALS INC's next catalyst?
ENANTA PHARMACEUTICALS INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Comparison of Efficacy of Tranexamic Acid Versus Vasopressin in Blood Loss Among Placenta Previa Pat" — expected August 31, 2026.
Who is the CEO of ENANTA PHARMACEUTICALS INC?
Dr. Jay R. Luly Ph.D. is the chief executive officer of ENANTA PHARMACEUTICALS INC (ENTA).
Where is ENANTA PHARMACEUTICALS INC headquartered?
ENANTA PHARMACEUTICALS INC (ENTA) is headquartered in Watertown, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.